» Articles » PMID: 27876591

Cystic Fibrosis and the Nervous System

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2016 Nov 24
PMID 27876591
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is a life-shortening autosomal recessive disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is an anion channel that conducts bicarbonate and chloride across cell membranes. Although defective anion transport across epithelial cells is accepted as the basic defect in CF, many of the features observed in people with CF and organs affected by CF are modulated by the nervous system. This is of interest because CFTR expression has been reported in both the peripheral and central nervous systems, and it is well known that the transport of anions, such as chloride, greatly modulates neuronal excitability. Thus it is predicted that in CF, lack of CFTR in the nervous system affects neuronal function. Consistent with this prediction, several nervous system abnormalities and nervous system disorders have been described in people with CF and in animal models of CF. The goal of this special feature article is to highlight the expression and function of CFTR in the nervous system. Special emphasis is placed on nervous system abnormalities described in people with CF and in animal models of CF. Finally, features of CF that may be modulated by or attributed to faulty nervous system function are discussed.

Citing Articles

A network medicine approach to investigating ME/CFS pathogenesis in severely ill patients: a pilot study.

Hung L, Wu C, Chang C, Li P, Hicks K, Dibble J Front Hum Neurosci. 2025; 19:1509346.

PMID: 39996021 PMC: 11847890. DOI: 10.3389/fnhum.2025.1509346.


Genetic alterations in the neuronal development genes are associated with changes of the tumor immune microenvironment in pancreatic cancer.

Mu K, Fu J, Gai J, Ravichandran H, Zheng L, Sun W Ann Pancreat Cancer. 2024; 6(10).

PMID: 38495381 PMC: 10942730. DOI: 10.21037/apc-23-13.


Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis.

Liou T, Argel N, Asfour F, Brown P, Chatfield B, Cox D iScience. 2024; 27(3):108835.

PMID: 38384849 PMC: 10879674. DOI: 10.1016/j.isci.2024.108835.


New Tic Disorder in a Child With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor.

Duehlmeyer S, Elson E, Oermann C J Pediatr Pharmacol Ther. 2024; 29(1):82-84.

PMID: 38332957 PMC: 10849685. DOI: 10.5863/1551-6776-29.1.82.


What the future holds: cystic fibrosis and aging.

Blankenship S, Landis A, Harrison Williams E, Lever J, Garcia B, Solomon G Front Med (Lausanne). 2024; 10:1340388.

PMID: 38264036 PMC: 10804849. DOI: 10.3389/fmed.2023.1340388.


References
1.
Deeks E . Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis. Drugs. 2016; 76(12):1191-201. DOI: 10.1007/s40265-016-0611-2. View

2.
Knowles M, Stutts M, Spock A, Fischer N, Gatzy J, Boucher R . Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science. 1983; 221(4615):1067-70. DOI: 10.1126/science.6308769. View

3.
Jahr C, Jessell T . ATP excites a subpopulation of rat dorsal horn neurones. Nature. 1983; 304(5928):730-3. DOI: 10.1038/304730a0. View

4.
Hamutcu R, Francis J, Karakoc F, Bush A . Objective monitoring of cough in children with cystic fibrosis. Pediatr Pulmonol. 2002; 34(5):331-5. DOI: 10.1002/ppul.10174. View

5.
Savage M, Brengelmann G, Buchan A, Freund P . Cystic fibrosis, vasoactive intestinal polypeptide, and active cutaneous vasodilation. J Appl Physiol (1985). 1990; 69(6):2149-54. DOI: 10.1152/jappl.1990.69.6.2149. View